The clear star of this year's American Society of Clinical Oncology (ASCO) meeting in Chicago was  the antibody approach to Programmed Death (PD-1) for solid tumors. Responses are greater than 50% and likely to be sustained. 

The initial target indications are melanoma and non-small cell lung cancer (NSCLC), due to the rich antigen environment for both. 

It's now a horse race between BMS and Merck to be the first to the market. Roche is playing catch-up with their antibody to the PD-1 ligand.